Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through two segments: Proteomics and Genomics. It provides SomaScan platform that enables researchers to measure thousands of proteins simultaneously, providing deep insights into biological processes and disease mechanism; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system redefines high-throughput genomics by delivering exceptional efficiency, precision, and scalability for qPCR applications. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Period	Debt/Equity
2015-12-31	2.22
2016-12-31	4.76
2017-12-31	8.29
2018-12-31	3.21
2019-12-31	0.72
2020-12-31	1.34
2021-12-31	1.91
2022-12-31	-1.97
2023-12-31	-1.08
2024-12-31	0.30

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LAB	$0.93	+0.32%	1.04M
3
4
5

Standard BioTools Inc. (LAB) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Standard BioTools Inc. Data in Excel

More LAB Financial Data